Climb Bio, Inc. (CLYM)
Nasdaq: CLYM · Pharmaceutical Preparations · Wellesley Hills, MA · filing with the SEC since 2019
Who owns Climb Bio, Inc.
As filed with the SECHolders of 5% or more
4
RA Capital Management, L.P. holds 33% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D/A filed Jul 7, 2026 says.
Directors and officers
18
report now, of 28 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Jul 7, 2026 · Common Stock, par value $0.0001 per share · 33% in Apr 29, 2026
Fmr LLC
SCHEDULE 13G · filed Jul 8, 2026 · COMMON STOCK
Pontifax VI G.P. L.P.
SCHEDULE 13G · filed Sep 18, 2025 · Common Stock, par value $0.0001 per share
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock
MPM BioImpact LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.6% in Feb 17, 2026
Ai Eti LLC
SCHEDULE 13D/A · filed Oct 16, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.66% in Oct 7, 2025
BML Investment Partners, L.P.
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
What CLYM reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Acquisition Agreement
A company bought · asset acquisition · owns, named in the 10-K filed Mar 5, 2026
Shares Converted Upon Acquisition
A company bought · acquisition · owns, named in the 10-K filed Mar 5, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 5, 2026.
Insider tradesForm 4
6sales
3purchases
6sales on a scheduled plan
2people selling
$2.7Msold, in dollars
$800,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Thomas Stephen Basil | director | 5 | $2.2M | 5 | 0 | $0 |
| Brennan Aoife | President and CEO | 1 | $400,000 | 1 | 0 | $0 |
| Kolchinsky Peter | director | 0 | $0 | 0 | 2 | $800,000 |
| Ra Capital Healthcare Fund LP | director | 0 | $0 | 0 | 1 | $0 |